Pasireotide in the treatment of neuroendocrine tumors: A review of the literature

Giovanni Vitale; Alessandra Dicitore; Concetta Sciammarella; Sergio Di Molfetta; Manila Rubino; Antongiulio Faggiano; Annamaria Colao

doi:10.1530/ERC-18-0010

Pasireotide in the treatment of neuroendocrine tumors: A review of the literature

Giovanni Vitale, Alessandra Dicitore, Concetta Sciammarella, Sergio Di Molfetta, Manila Rubino, Antongiulio Faggiano, Annamaria Colao

Research output: Contribution to journal › Review article

Abstract

Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.

Original language	English
Pages (from-to)	R351-R364
Journal	Endocrine-Related Cancer
Volume	25
Issue number	6
DOIs	https://doi.org/10.1530/ERC-18-0010
Publication status	Published - Jun 1 2018

Keywords

Neuroendocrine tumors
Pasireotide
Somatostatin analogs
Somatostatin receptors

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Oncology
Endocrinology
Cancer Research

Access to Document

10.1530/ERC-18-0010

Fingerprint Dive into the research topics of 'Pasireotide in the treatment of neuroendocrine tumors: A review of the literature'. Together they form a unique fingerprint.

Cite this

Vitale, G., Dicitore, A., Sciammarella, C., Di Molfetta, S., Rubino, M., Faggiano, A., & Colao, A. (2018). Pasireotide in the treatment of neuroendocrine tumors: A review of the literature. Endocrine-Related Cancer, 25(6), R351-R364. https://doi.org/10.1530/ERC-18-0010

@article{2f34ef308d5747c6a4851c1d23186abf,

title = "Pasireotide in the treatment of neuroendocrine tumors: A review of the literature",

abstract = "Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.",

keywords = "Neuroendocrine tumors, Pasireotide, Somatostatin analogs, Somatostatin receptors",

author = "Giovanni Vitale and Alessandra Dicitore and Concetta Sciammarella and {Di Molfetta}, Sergio and Manila Rubino and Antongiulio Faggiano and Annamaria Colao",

year = "2018",

month = jun,

day = "1",

doi = "10.1530/ERC-18-0010",

language = "English",

volume = "25",

pages = "R351--R364",

journal = "Endocrine-Related Cancer",

issn = "1351-0088",

publisher = "BioScientifica Ltd.",

number = "6",

}

TY - JOUR

T1 - Pasireotide in the treatment of neuroendocrine tumors

T2 - A review of the literature

AU - Vitale, Giovanni

AU - Dicitore, Alessandra

AU - Sciammarella, Concetta

AU - Di Molfetta, Sergio

AU - Rubino, Manila

AU - Faggiano, Antongiulio

AU - Colao, Annamaria

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.

AB - Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.

KW - Neuroendocrine tumors

KW - Pasireotide

KW - Somatostatin analogs

KW - Somatostatin receptors

UR - http://www.scopus.com/inward/record.url?scp=85047477909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047477909&partnerID=8YFLogxK

U2 - 10.1530/ERC-18-0010

DO - 10.1530/ERC-18-0010

M3 - Review article

AN - SCOPUS:85047477909

VL - 25

SP - R351-R364

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 6

ER -